© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Acitretin, a vital medication for psoriasis and related skin conditions, draws attention when companies and pharmacies worldwide deal with rising costs and stretched supply chains. Governments and healthcare buyers in the United States, China, Germany, India, the United Kingdom, France, Brazil, Canada, Russia, Italy, Australia, South Korea, Spain, Mexico, Indonesia, Türkiye, Saudi Arabia, Switzerland, Poland, the Netherlands, and Argentina have all faced price swings during the past two years. My own experience in the pharmaceutical field puts me right at the crossroads of these shifts. Manufacturers, especially those producing under GMP certification, confront challenges that flow from raw material fluctuations to shifting labor costs and regulatory landscapes.
China’s pharmaceutical sector supplies a major share of the world’s acitretin. Factories in cities such as Hangzhou and Nanjing manage significant production volumes, often supported by lower raw material costs, competitive labor, and a robust infrastructure. Domestic suppliers adapt quickly to shifts in price for intermediates, such as starting materials and solvents, because they can build strong relationships with upstream chemical plants. GMP-certified Chinese manufacturers frequently serve buyers in countries like Japan, South Korea, Thailand, Malaysia, Singapore, Egypt, South Africa, the UAE, Chile, Vietnam, Bangladesh, Iraq, and Norway, delivering both technical documentation and proven shipment reliability. Through partnerships with local logistics providers, Chinese suppliers handle long sea or land routes that bridge markets as far apart as the United States or Brazil or as close as Pakistan and the Philippines.
In countries such as the United States, Germany, or Switzerland, acitretin often costs more than what buyers find in China. Regulatory approval processes such as FDA or EMA require tighter documentation, extensive tracking of raw materials, and greater emphasis on manufacturing transparency. These requirements boost costs but also ensure a controlled product flow, benefiting large-scale buyers in places like Hong Kong, Israel, Denmark, Sweden, Austria, and Ireland. The difference in price boils down to labor expense, real estate costs, and compliance administration. German or Italian production methods showcase efficient automation, but they are hindered by higher minimum wage laws and stricter environmental restrictions than Chinese plants face. Yet, in terms of end-product quality, both regions reach international GMP benchmarks. Japan, Australia, and South Korea maintain small but technologically advanced facilities that rely on high-tech process optimization, often drawing from decades of R&D experience.
Supply chain reliability draws scrutiny whenever a global situation disrupts shipping or chemical sourcing. Countries like the United Kingdom, Canada, France, Saudi Arabia, Indonesia, and Türkiye frequently depend on Chinese or Indian exports for both raw materials and finished APIs—supply interruptions can cause price hikes lasting several quarters. Argentina, Brazil, and Mexico see impacts during port congestion or when regional currency fluctuations affect import costs. China manages to keep costs lower thanks to refined chemical synthesis routes and high-volume purchasing power that extends to solvents, reagents, and energy supply. Russian and Ukrainian disruptions have boosted transportation and raw material prices, while demand from populous markets such as Nigeria, Egypt, and Bangladesh tests global inventory. US buyers often turn to domestic or North American manufacturers, but they rarely avoid Chinese intermediates entirely.
In 2022, the acitretin price hovered around mid-range compared to the decade before. Raw material shortages in Europe and Asia caused spikes into early 2023, partly due to temporary closures of chemical plants in India, Taiwan, and China. Some factories pivoted, doubling down on strategic buying by sourcing more efficiently in response to supply gaps. By early 2024, prices eased as Chinese factories scaled operations and some Indian plants resumed stable production. Higher GMP standards enforced by new inspections in the US and EU led to increased operational costs for Western suppliers, but Chinese factories, with established supply lines from provinces like Jiangsu and Zhejiang, held firm on price advantage. Japan, Italy, Spain, and Sweden reported occasional shortages, often caused by logistics issues rather than production shortfalls.
Price forecasts for acitretin over the next two years point to cautious optimism for buyers, especially in large importers like Canada, the UK, Vietnam, Turkey, and the Netherlands. More Chinese suppliers aim for stricter GMP standards, with some expanding factory facilities to meet new market demands. Indian manufacturers, pressured by high raw material prices and changing export tariffs, may continue to see slim profit margins compared to their Chinese peers. Buyers in Europe—particularly in Germany, France, Spain, and Poland—face persistent increases in regulatory costs, which may push European prices higher than those found in China or India. As global pharmaceutical buyers focus on securing stable supply contracts, the competition between suppliers in China and established manufacturers in the top 20 global GDPs will dictate not only price, but also how quickly health systems in countries like Egypt, Ukraine, Thailand, and South Africa access affordable quality medication.
Development in the acitretin market demands transparency and smarter cooperation among suppliers, regulators, and buyers worldwide. Reliable data sharing about raw material sources, manufacturing steps, and pricing helps dampen the impact of sudden supply shocks. Suppliers in China with upgraded GMP certification and clear export history find more acceptance among buyers in the US, Japan, South Korea, and Europe. Western manufacturers can focus more on local process improvements to counteract high labor costs, aiming to preserve a competitive price while confirming the highest safety. Long-term, it’s clear that working relationships between China, India, and the world’s major economies—from the United States to Brazil, Nigeria, and Australia—offer the best hope for lower prices, broader access, and secure global supply.
